MAP
ALNY icon

Moody Aldrich Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Moody Aldrich Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,138
Closed -$320K – 196
2024
Q1 		$320K Sell
2,138
-1,147
-35% -$191K 0.05% 171
2023
Q4 		$629K Buy
3,285
+1,002
+44% +$171K 0.11% 126
2023
Q3 		$404K Buy
+2,283
New +$436K 0.08% 140

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Moody Aldrich Partners's ALNY Position: Q2 2024 in Review

Moody Aldrich Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 2,138 shares — an estimated $320K sold.

Moody Aldrich Partners first reported a position in ALNY in Q3 2023 and held it in 3 quarters. The position peaked at $629K in Q4 2023. 521 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

  • Moody Aldrich Partners reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Moody Aldrich Partners sold 2,138 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $320K.
  • Moody Aldrich Partners first reported a position in Alnylam Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Moody Aldrich Partners's Alnylam Pharmaceuticals position peaked at $629K in Q4 2023.
  • 521 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Moody Aldrich Partners's 13F filing for Q2 2024, filed 24 Jul 2024.